WELLCOME RETROVIR FOR PERINATAL HIV TRANSMISSION, HIVID COMBO OKAYED 11 DAYS POST-ADVISORY CMTE.; PHS MATERNAL/FETAL HIV ZIDOVUDINE GUIDELINES OUT
Executive Summary
Burroughs-Wellcome's Retrovir (zidovudine, AZT) will carry two new indications based on Aug. 8 approvals from FDA: prevention of maternal/fetal HIV transmission and treatment of HIV in combination with Hoffmann-La Roche's Hivid (zalcitabine, ddC).